Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
PFE
2 articles
Reason Happily Pfizer (PFE): A Buy-And-Hold Case Strategy
Curious about a long term reason to own Pfizer? This guide lays out a practical, actionable case for buying and holdi...